Eli Lilly Acquires Kelonia Therapeutics for $3 Billion as Biotech Sector Sees New Developments
Eli Lilly completed a $3 billion acquisition of Kelonia Therapeutics, according to reports. A venture capital partner shared the original investment memo and slide deck for Kelonia. Other biotech news includes BioAge's inflammation trial results, a Pfizer executive departure, and the launch of Tortugas Neuroscience.
Substrate placeholder — needs reviewEli Lilly acquired Kelonia Therapeutics for $3 billion, @statnews reported. A partner at the venture capital firm that incubated Kelonia Therapeutics shared the original investment memo and slide deck used to start Kelonia, following the acquisition news. BioAge is developing drugs targeting inflammation to treat chronic conditions, the company stated.
BioAge's experimental pill aimed at reducing heart risks reduced inflammation in an early trial, according to BioAge. A former banker brought on to revitalize Pfizer’s strategy departed his post on April 20, 2026, @statnews reported. Tortugas Neuroscience launched on April 21, 2026, to develop drugs for brain disorders and other conditions.
In an early trial, CAR-T results raised hope of preventing multiple myeloma in high-risk patients, @statnews reported. The STAT Plus Newsletter The Readout was published on April 21, 2026, via STAT. Elaine Chen is the National Biotech Reporter for STAT.
Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast The Readout Loud. 70. At AACR on April 20, 2026, there was a provocative use of CAR-T, Merck’s new development, and discussion of cancer’s geography problem, @statnews reported.
STAT Plus reported on April 20, 2026, about early trial CAR-T results for multiple myeloma prevention. The article was written by Elaine Chen on April 21, 2026.
Key Facts
Story Timeline
6 events- 2026-04-21
Tortugas Neuroscience launched to develop drugs for brain disorders and other conditions.
1 source@statnews - 2026-04-21
The STAT Plus Newsletter The Readout was published.
1 source@statnews - 2026-04-21
The article was written by Elaine Chen.
1 source@statnews - 2026-04-20
A former banker brought on to revitalize Pfizer’s strategy departed his post.
1 source@statnews - 2026-04-20
At AACR, there was a provocative use of CAR-T, Merck’s new development, and discussion of cancer’s geography problem.
1 source@statnews - 2026-04-20
STAT Plus reported about early trial CAR-T results for multiple myeloma prevention.
1 source@statnews
Potential Impact
- 01
The acquisition could accelerate Kelonia's gene therapy projects under Eli Lilly's resources.
- 02
Tortugas Neuroscience launch could introduce new treatments for brain disorders.
- 03
BioAge's positive trial results may attract further investment in inflammation-targeted drugs.
- 04
CAR-T advancements may shift preventive approaches in multiple myeloma care.
- 05
Pfizer's executive departure might delay strategic revitalization efforts.
Transparency Panel
Related Stories
NprWHO Director Visits Congo as Ebola Outbreak Spreads
The head of the World Health Organization arrived in Kinshasa to support efforts against a rare Ebola strain. Health workers face equipment shortages, community distrust, and armed conflict in affected provinces.
medpagetoday.comFDA Panel Recommends XFG Variant for Fall Covid Shots
Replimune will submit an application to the FDA for the third time. Pfizer and Innovent Biologics reached a collaboration agreement valued at up to $10.5 billion.
Benzinga Publishes Article on Biotech Stocks During Pandemic Recovery
Benzinga published an article titled 'Best Biotech Stocks Right Now' that addresses the sector's position during global recovery from the pandemic. The piece notes government institutions and professional traders are focusing on biotech companies for vaccine and booster developme…